Sherwin-Williams reported a 6.8% year-over-year increase in net sales for Q1 2026, driven by its Suvinil acquisition and price hikes. Despite soft demand in the end markets, the company leverages its extensive store network and pricing power to maintain resilient growth. Trading at a forward P/E of 27, Sherwin-Williams is slightly undervalued with a fair value estimate of $322 per share. The company boasts a 47-year streak of dividend growth and projects a 10.5% compound annual growth rate in earnings per share, aiming for over 11% annualized total returns through 2031.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
